Filing Flows › Axsome Therapeutics (AXSM) › Q3 2026 › vs Q3 2025
Axsome Therapeutics (AXSM) Q3 2026 vs Q3 2025 (year over year)
Axsome Therapeutics's revenue rose $88.7M (+52%) from $171M in Q3 2025 to $260M in Q3 2026. The biggest changes: Product +$80.2M (+47%); Royalty and Milestone Revenue +$8.5M (+706%).
Axsome Therapeutics, Q3 2026: revenue $260M (+52% year over year), operating margin -4.3%, net loss $12.9M, operating cash flow −$9.5M. The chart draws each line against Q3 2025, the increases inside each band.
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Product | $250M | $170M | $80.2M | +47% |
| Royalty and Milestone Revenue | $9.7M | $1.2M | $8.5M | +706% |
| Revenue | $260M | $171M | $88.7M | +52% |
| Net loss | $12.9M | $47.2M | −$34.4M | -73% |
| Costs & expenses | $273M | $218M | $54.3M | +25% |
| Operating costs | $271M | $217M | $53.7M | +25% |
| Interest & other, net | $1.7M | $1.1M | $601K | +54% |
| Income tax | $88K | $0 | $88K | — |
| Cost of revenue | $17.8M | $11.9M | $5.9M | +49% |
| Research & development | $50.6M | $40.2M | $10.5M | +26% |
| SG&A | $203M | $150M | $52.9M | +35% |
| Operating cash sources | $37.6M | $23.8M | $13.8M | +58% |
| Depreciation & amortization | $1.7M | $1.7M | $8K | +0.5% |
| Share-based compensation | $26.4M | $23.1M | $3.3M | +14% |
| Cash used in operations | $9.5M | −$1.0M | $10.5M | — |
| Net loss absorbed | $12.9M | $47.2M | −$34.4M | -73% |
| Working capital & other | $24.7M | −$23.4M | $48.1M | — |
Questions
How much did Axsome Therapeutics's revenue grow year over year in Q3 2026?
Axsome Therapeutics's revenue rose $88.7M (+52%) from $171M in Q3 2025 to $260M in Q3 2026.
What drove Axsome Therapeutics's revenue change in Q3 2026?
Product +$80.2M (+47%); Royalty and Milestone Revenue +$8.5M (+706%).